OIG: PROVISION OF FREE DRUGS BY DRUG MANUFACTURER TO ELIGIBLE PATIENTS PRESENTS LOW RISK OF FRAUD AND ABUSE AND DOES NOT IMPLICATE BENEFICIARY INDUCEMENTS CMP
March 30, 2021 In Advisory Opinion 21-01, issued January 8, 2021, the OIG recently determined that an arrangement whereby a drug manufacturer provides a free drug to patients meeting specific… Read more »